Aspiriant LLC’s MetLife MET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$285K Buy
4,024
+599
+17% +$44.8K 0.01% 287
2025
Q4
$270K Buy
3,425
+214
+7% +$16.9K 0.01% 287
2025
Q3
$264K Sell
3,211
-655
-17% -$51.5K 0.01% 269
2025
Q2
$311K Buy
3,866
+530
+16% +$40.9K 0.01% 247
2025
Q1
$268K Buy
3,336
+115
+4% +$9.56K 0.01% 249
2024
Q4
$264K Buy
3,221
+3
+0.1% +$250 0.01% 249
2024
Q3
$265K Buy
3,218
+17
+0.5% +$1.27K 0.01% 249
2024
Q2
$225K Sell
3,201
-1,095
-25% -$78.2K 0.01% 262
2024
Q1
$318K Buy
4,296
+88
+2% +$6.13K 0.01% 238
2023
Q4
$278K Buy
4,208
+95
+2% +$5.95K 0.01% 254
2023
Q3
$259K Buy
4,113
+297
+8% +$18.5K 0.01% 241
2023
Q2
$216K Sell
3,816
-26
-0.7% -$1.44K 0.01% 267
2023
Q1
$223K Buy
3,842
+98
+3% +$6.61K 0.01% 259
2022
Q4
$271K Buy
3,744
+243
+7% +$17.4K 0.01% 225
2022
Q3
$213K Buy
3,501
+113
+3% +$7.22K 0.01% 243
2022
Q2
$213K Buy
3,388
+42
+1% +$2.78K 0.01% 258
2022
Q1
$235K Buy
+3,346
New +$226K 0.01% 251
2018
Q2
Sell
-4,600
Closed -$211K 257
2018
Q1
$211K Buy
+4,600
New +$223K 0.02% 226

Other funds holding MET

Aspiriant LLC's MET Position: Q1 2026 in Review

Aspiriant LLC increased its MetLife (MET) stake by 17% in Q1 2026, buying an estimated $44.8K and bringing the position to 4,024 shares worth $285K. The position accounts for 0.01% of the portfolio, ranked #287.

Aspiriant LLC first reported a position in MET in Q1 2018 and has held it in 18 quarters since. The position peaked at $318K in Q1 2024. 1,371 funds tracked by Wall St. Rank hold MET as of Q1 2026.

  • Aspiriant LLC held 4,024 shares of MetLife worth $285K as of Q1 2026.
  • Aspiriant LLC bought 599 MetLife shares in Q1 2026, an estimated $44.8K.
  • MetLife made up 0.01% of Aspiriant LLC's portfolio in Q1 2026, its #287 holding.
  • Aspiriant LLC first reported a position in MetLife in Q1 2018 and has held it in 18 quarters since.
  • Aspiriant LLC's MetLife position peaked at $318K in Q1 2024.
  • 1,371 funds tracked by Wall St. Rank held MetLife as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.